Newsroom | Alcon
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
Alcon - News and Events - Press Releases
Selecting a category value will change the news content. Select Category: Contact Alcon Investor Relations +41 589 112 110 +1 817 615 2789 investor.relations@alcon.com. Computershare. …
Alcon - Alcon Debuts Groundbreaking PRECISION7, a One-Week …
Nov 7, 2024 · GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of …
Alcon Reports Second-Quarter 2024 Results with Strong Growth …
Aug 20, 2024 · Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share 2 of $0.74 in the second quarter of 2024.
Alcon - Alcon's Broad Portfolio Delivers Robust Sales and …
Feb 27, 2024 · Today, Alcon will issue its 2023 Annual Report, which will be available on https://investor.alcon.com/financials/annual-reports/default.aspx. Alcon will also file its 2023 …
Alcon Inc. (ALC) Latest Press Releases & Corporate News - Yahoo Finance
Get the latest Alcon Inc. (ALC) stock news and headlines to help you in your trading and investing decisions.
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
Jan 10, 2024 · Approval will position Alcon to start selling a first-in-class treatment for dry eye disease, a condition that the company says affects an estimated 38 million people in the U.S. …
Alcon Inc. (ALC) Latest Stock News & Headlines - Yahoo Finance
Get the latest Alcon Inc. (ALC) stock news and headlines to help you in your trading and investing decisions.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic …
Sep 20, 2024 · Major Concerns for Alcon Stock. Alcon is experiencing inflationary pressures in electronic components, freight, labor, resins and plastics, which is impacting the company’s …
Alcon - Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its ...
Aug 22, 2022 · Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1; Adds Rocklatan ® and Rhopressa ®, and a pipeline of …